Psychological outcomes (quality of life, anxiety and depressive symptoms, pain, and fatigue) in patients with a hematological malignancy treated with hematopoietic cell transplantation Mental and Behavioural Disorders
Conditions
Interventions
After providing informed consent, participants will be randomly assigned to either the experimental group receiving the intervention or the control group. Allocation will be done following a permutate
Sponsors
Hôpital Maisonneuve-Rosemont
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Over 18 years old 2. Undergoing autologous or allogeneic HCT for a hematologic malignancy 3. Sufficiently fluent in French to fully understand the recorded hypnosis sessions
Exclusion criteria
Exclusion criteria: 1. Being treated with a HCT at home 2. Received HCT previously 3. Significant cognitive or psychiatric disorders impairing communication with others 4. Sensory impairments (deafness, blindness) that impact participation in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life measured by the Functional Assessment of Cancer Therapy – Bone Marrow Transplantation (FACT-BMT) questionnaire at pre-transplant (T0: baseline), before the intervention (T1: day +7 ± 1 day post-transplant), after the intervention (T2: day +21 ± 1 day post-transplant), and at 1 month (T3: day +28 ± 2 days) and 3 months (T4: day +100 ±10 days) post-HCT. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Quality of life Social/Family subscale scores measured by the specific subscale of the Functional Assessment of Cancer Therapy – Bone Marrow Transplantation (FACT-BMT) at pre-transplant (T0: baseline), before the intervention (T1: day +7 ± 1 day post-transplant), after the intervention (T2: day +21 ± 1 day post-transplant), and at 1 month (T3: day +28 ± 2 days) and 3 months (T4: day +100 ±10 days) post-HCT. 2. Quality of life Emotional subscale scores measured by the specific subscale of the Functional Assessment of Cancer Therapy – Bone Marrow Transplantation (FACT-BMT) questionnaire at pre-transplant (T0: baseline), before the intervention (T1: day +7 ± 1 day post-transplant), after the intervention (T2: day +21 ± 1 day post-transplant), and at 1 month (T3: day +28 ± 2 days) and 3 months (T4: day +100 ±10 days) post-HCT. 3. Quality of life Functional subscale scores measured by the specific subscale of the Functional Assessment of Cancer Therapy – Bone Marrow Transplantation (FACT-BMT) questionnaire at pre-transplant (T0: baseline), before the intervention (T1: day +7 ± 1 day post-transplant), after the intervention (T2: day +21 ± 1 day post-transplant), and at 1 month (T3: day +28 ± 2 days) and 3 months (T4: day +100 ±10 days) post-HCT. 4. Quality of life Transplant-Specific subscale scores measured by the specific subscale of the Functional Assessment of Cancer Therapy – Bone Marrow Transplantation (FACT-BMT) questionnaire at pre-transplant (T0: baseline), before the intervention (T1: day +7 ± 1 day post-transplant), after the intervention (T2: day +21 ± 1 day post-transplant), and at 1 month (T3: day +28 ± 2 days) and 3 months (T4: day +100 ±10 days) post-HCT. 5. Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS) at pre-transplant (T0: baseline), before the intervention (T1: day +7 ± 1 day post-transplant), after the intervention (T2: day +21 ± 1 day post-transplant), and at 1 month (T3: day +28 ± 2 days) and 3 month | — |
Countries
Canada
Contacts
Public ContactValentyn Fournier
Outcome results
None listed